[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse SOX2

Summary
SymbolSOX2
NameSRY (sex determining region Y)-box 2
Aliases ANOP3; MCOPS3; SRY-related HMG-box gene 2; sex determining region Y-box 2; transcription factor SOX2; Transc ......
Chromosomal Location3q26.3-q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Nucleus.
Domain PF00505 HMG (high mobility group) box
PF12336 SOX transcription factor
Function

Transcription factor that forms a trimeric complex with OCT4 on DNA and controls the expression of a number of genes involved in embryonic development such as YES1, FGF4, UTF1 and ZFP206 (By similarity). Critical for early embryogenesis and for embryonic stem cell pluripotency. May function as a switch in neuronal development. Downstream SRRT target that mediates the promotion of neural stem cell self-renewal (By similarity). Keeps neural cells undifferentiated by counteracting the activity of proneural proteins and suppresses neuronal differentiation (By similarity).

> Gene Ontology
 
Biological Process GO:0001503 ossification
GO:0001649 osteoblast differentiation
GO:0001654 eye development
GO:0001704 formation of primary germ layer
GO:0001706 endoderm formation
GO:0001708 cell fate specification
GO:0001711 endodermal cell fate commitment
GO:0001714 endodermal cell fate specification
GO:0007050 cell cycle arrest
GO:0007369 gastrulation
GO:0007423 sensory organ development
GO:0007492 endoderm development
GO:0010001 glial cell differentiation
GO:0010721 negative regulation of cell development
GO:0016055 Wnt signaling pathway
GO:0019827 stem cell population maintenance
GO:0021536 diencephalon development
GO:0021781 glial cell fate commitment
GO:0021983 pituitary gland development
GO:0021984 adenohypophysis development
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0030111 regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0030900 forebrain development
GO:0031099 regeneration
GO:0035019 somatic stem cell population maintenance
GO:0035270 endocrine system development
GO:0035987 endodermal cell differentiation
GO:0042063 gliogenesis
GO:0042246 tissue regeneration
GO:0043281 regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0043410 positive regulation of MAPK cascade
GO:0043583 ear development
GO:0045165 cell fate commitment
GO:0045665 negative regulation of neuron differentiation
GO:0045785 positive regulation of cell adhesion
GO:0045786 negative regulation of cell cycle
GO:0048732 gland development
GO:0048839 inner ear development
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050680 negative regulation of epithelial cell proliferation
GO:0050768 negative regulation of neurogenesis
GO:0051961 negative regulation of nervous system development
GO:0052547 regulation of peptidase activity
GO:0052548 regulation of endopeptidase activity
GO:0060070 canonical Wnt signaling pathway
GO:0060795 cell fate commitment involved in formation of primary germ layer
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0090090 negative regulation of canonical Wnt signaling pathway
GO:0097150 neuronal stem cell population maintenance
GO:0098727 maintenance of cell number
GO:0198738 cell-cell signaling by wnt
GO:2000116 regulation of cysteine-type endopeptidase activity
Molecular Function GO:0000982 transcription factor activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0001228 transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific binding
GO:0035198 miRNA binding
Cellular Component GO:0005667 transcription factor complex
> KEGG and Reactome Pathway
 
KEGG hsa04390 Hippo signaling pathway
hsa04550 Signaling pathways regulating pluripotency of stem cells
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-3769402: Deactivation of the beta-catenin transactivating complex
R-HSA-1266738: Developmental Biology
R-HSA-168256: Immune System
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-2892247: POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation
R-HSA-2892245: POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation
R-HSA-162582: Signal Transduction
R-HSA-449147: Signaling by Interleukins
R-HSA-195721: Signaling by Wnt
R-HSA-201681: TCF dependent signaling in response to WNT
R-HSA-452723: Transcriptional regulation of pluripotent stem cells
Summary
SymbolSOX2
NameSRY (sex determining region Y)-box 2
Aliases ANOP3; MCOPS3; SRY-related HMG-box gene 2; sex determining region Y-box 2; transcription factor SOX2; Transc ......
Chromosomal Location3q26.3-q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SOX2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between SOX2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27015306Lung Carcinoma; Breast CarcinomaInhibit immunityLCC cells show stem-cell-like characteristics and express SOX2 and SOX9 transcription factors, which are essential for their survival in host organs under immune surveillance and for metastatic outgrowth under permissive conditions.
24599129OligodendrogliomaInhibit immunitySox2 is required to maintain cancer stem cells in a mouse model of high-grade oligodendroglioma. In support of this possibility, an immunotherapeutic approach based on immunization of mice with SOX2 peptides delayed tumor development and prolonged survival.
17375044Malignant GliomaInhibit immunitySOX2 was identified by screening an expression database for transcripts that are overexpressed in malignant glioma, but display minimal expression in normal tissues.? Human leucocyte antigen-A(*)0201-restricted SOX2-derived peptides were tested for the activation of glioma-reactive CD8+ cytotoxic T lymphocytes (CTLs). Specific CTLs were raised against the peptide TLMKKDKYTL and were capable of lysing glioma cells. The abundant and glioma-restricted overexpression of SOX2 and the generation of SOX2-specific and tumour-reactive CTLs may recommend this antigen as target for T-cell-based immunotherapy of glioma.
29769207Head and Neck Squamous Cell CarcinomaInhibit immunitySOX2 potentiates an immunosuppressive microenvironment and promotes HNSCC growth in vivo in an IFN-I-dependent fashion. SOX2 dampens the immunogenicity of HNSCC by targeting the STING pathway for degradation.
Summary
SymbolSOX2
NameSRY (sex determining region Y)-box 2
Aliases ANOP3; MCOPS3; SRY-related HMG-box gene 2; sex determining region Y-box 2; transcription factor SOX2; Transc ......
Chromosomal Location3q26.3-q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SOX2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSOX2
NameSRY (sex determining region Y)-box 2
Aliases ANOP3; MCOPS3; SRY-related HMG-box gene 2; sex determining region Y-box 2; transcription factor SOX2; Transc ......
Chromosomal Location3q26.3-q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SOX2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.9860.177
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-2.1080.139
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1560.888
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.9250.287
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.4550.271
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2520.867
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5770.619
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-1.0860.511
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11122.3720.168
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.0270.964
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.3740.646
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1940.629
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SOX2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211705.9-5.90.447
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131109.1-9.10.458
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolSOX2
NameSRY (sex determining region Y)-box 2
Aliases ANOP3; MCOPS3; SRY-related HMG-box gene 2; sex determining region Y-box 2; transcription factor SOX2; Transc ......
Chromosomal Location3q26.3-q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SOX2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSOX2
NameSRY (sex determining region Y)-box 2
Aliases ANOP3; MCOPS3; SRY-related HMG-box gene 2; sex determining region Y-box 2; transcription factor SOX2; Transc ......
Chromosomal Location3q26.3-q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SOX2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SOX2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSOX2
NameSRY (sex determining region Y)-box 2
Aliases ANOP3; MCOPS3; SRY-related HMG-box gene 2; sex determining region Y-box 2; transcription factor SOX2; Transc ......
Chromosomal Location3q26.3-q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SOX2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSOX2
NameSRY (sex determining region Y)-box 2
Aliases ANOP3; MCOPS3; SRY-related HMG-box gene 2; sex determining region Y-box 2; transcription factor SOX2; Transc ......
Chromosomal Location3q26.3-q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SOX2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSOX2
NameSRY (sex determining region Y)-box 2
Aliases ANOP3; MCOPS3; SRY-related HMG-box gene 2; sex determining region Y-box 2; transcription factor SOX2; Transc ......
Chromosomal Location3q26.3-q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SOX2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSOX2
NameSRY (sex determining region Y)-box 2
Aliases ANOP3; MCOPS3; SRY-related HMG-box gene 2; sex determining region Y-box 2; transcription factor SOX2; Transc ......
Chromosomal Location3q26.3-q27
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SOX2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.